Nucleic Acid Testing for Coronavirus Disease 2019: Demand, Research Progression, and Perspective

Area of Science:

• Virology
• Molecular Diagnostics
• Public Health

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, necessitates rapid and accurate diagnostic tools.
• Nucleic acid testing (NAT) is the gold standard for COVID-19 diagnosis due to its high sensitivity and specificity.
• A surge in demand for COVID-19 diagnostic reagents has led to numerous products entering the market.

Purpose of the Study:

• To provide an overview of available COVID-19 NAT products.
• To analyze the principles, advantages, and disadvantages of different NAT assays.
• To guide assay developers and clinical staff in selecting appropriate diagnostic tests.

Main Methods:

• Review of COVID-19 NAT products currently available.
• Analysis of assay principles, including sensitivity, specificity, and turnaround time.
• Evaluation of clinical application scenarios and roles in epidemic containment.

Main Results:

• Over 600 research units and companies have developed COVID-19 NAT reagents.
• Exaggerated claims and lack of understanding have caused chaos in clinical diagnosis.
• Different NAT products have varying strengths and weaknesses for specific applications.

Conclusions:

• A clear understanding of NAT product characteristics is essential for effective COVID-19 diagnosis and control.
• Guidance is needed for clinicians to select the most appropriate NAT assays.
• Standardization and clear communication regarding NAT product performance are critical.